Literature DB >> 6694261

Identification of immunologically cross-reactive proteins of Sindbis virus: evidence for unique conformation of E1 glycoprotein from infected cells.

J A Wolcott, C J Wust, A Brown.   

Abstract

Hyperimmune antisera to purified Sindbis (SIN) or Semliki Forest (SF) virus were used to identify alphavirus-specific and cross-reactive proteins in virions and infected cells. The hyperimmune sera participated in homologous and cross-cytolysis of alphavirus-infected cells, and the use of monospecific antisera to SIN structural proteins suggested that E1 and E2 could serve as target proteins in cytolysis. Proteins from purified virions or infected cells were extracted with Nonidet P-40, denatured by procedures for sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose solid supports, and reacted with hyperimmune sera and 125I-labeled protein A (immunoblotting on denatured proteins). Alternatively, native proteins extracted by mild Nonidet P-40 treatment were precipitated with hyperimmune sera before denaturation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After immunoblotting, homologous antiserum reacted with the virus structural proteins E1, E2, capsid extracted from purified virions, and the counterparts of these proteins extracted from infected cells. In addition, PE2 and a 92,000-molecular-weight protein from infected cells reacted with homologous antiserum. These proteins were also immunoprecipitated with homologous antiserum. After immunoblotting, the Sindbis capsid protein was shown to be cross-reactive whether derived from purified virions or from infected cells; no cross-reactivity was observed with PE2 or E2 from either source, and the E1 glycoprotein was shown to be cross-reactive only when obtained from virions. However, the E1 glycoprotein could be cross-immunoprecipitated from infected cells (as well as from disrupted virions), and, in addition, capsid and a 92,000-molecular-weight protein were cross-immunoprecipitated from infected cells. These results suggest that a native conformation of the cell-associated E1 glycoproteins may be required for immunological cross-reactivity (immune precipitation), whereas virion but not cell-associated E1 retains immunological cross-reactivity after denaturation (immunoblot technique). The findings extend our previously published evidence which suggested that alphavirus maturation is accompanied by a change in immunological cross-reactivity with respect to E1.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694261      PMCID: PMC255476     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Antibody-dependent, complement-mediated homologous and cross-cytolysis of togavirus-infected cells.

Authors:  B King; C J Wust; A Brown
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

2.  Envelopments of Sindbis virus: synthesis and organization of proteins in cells infected with wild type and maturation-defective mutants.

Authors:  J F Smith; D T Brown
Journal:  J Virol       Date:  1977-06       Impact factor: 5.103

3.  Reversible denaturation of enzymes by sodium dodecyl sulfate.

Authors:  K Weber; D J Kuter
Journal:  J Biol Chem       Date:  1971-07-25       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Envelope antigens of Sindbis virus in cells infected with temperature-sensitive mutants.

Authors:  J W Bell; M R Waite
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

6.  Properties of monoclonal antibodies directed against the glycoproteins of Sindbis virus.

Authors:  J T Roehrig; D Gorski; M J Schlesinger
Journal:  J Gen Virol       Date:  1982-04       Impact factor: 3.891

7.  Association of sindbis virion glycoproteins and their precursors.

Authors:  C M Rice; J H Strauss
Journal:  J Mol Biol       Date:  1982-01-15       Impact factor: 5.469

8.  Antigenic characterization of two sindbis envelope glycoproteins separated by isoelectric focusing.

Authors:  J M Dalrymple; S Schlesinger; P K Russell
Journal:  Virology       Date:  1976-01       Impact factor: 3.616

9.  Application of a novel radioimmunoassay to identify baculovirus structural proteins that share interspecies antigenic determinants.

Authors:  G E Smith; M D Summers
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

10.  Large-molecular-weight precursors of sindbis virus proteins.

Authors:  M J Schlesinger; S Schlesinger
Journal:  J Virol       Date:  1973-06       Impact factor: 5.103

View more
  5 in total

1.  Fusion of Semliki Forest virus infected Aedes albopictus cells at low pH is a fusion from within.

Authors:  A Omar; A Flaviano; U Kohler; H Koblet
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Infection of a human leukemia K-562 cell line with Semliki Forest virus.

Authors:  D D King; B Brady; D Dodd; C J Wust; A Brown
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Detection of Semliki Forest virus in cell culture by use of an enzyme immunoassay with peroxidase-labeled monoclonal antibodies specific for glycoproteins E1 and E2.

Authors:  F H van Tiel; W A Boere; J Vinjé; T Harmsen; B J Benaissa-Trouw; C A Kraaijeveld; H Snippe
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

4.  Detection of immunologically cross-reacting capsid protein of alphaviruses on the surfaces of infected L929 cells.

Authors:  C Smith; J A Wolcott; C J Wust; A Brown
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

5.  A duplex real-time reverse transcriptase polymerase chain reaction assay for the detection of St. Louis encephalitis and eastern equine encephalitis viruses.

Authors:  Rene Hull; Seela Nattanmai; Laura D Kramer; Kristen A Bernard; Norma P Tavakoli
Journal:  Diagn Microbiol Infect Dis       Date:  2008-08-20       Impact factor: 2.803

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.